Search results for

The generic pharmaceutical industry had a recent victory on appeal, in Sigma Pharmaceuticals (Australia) v Wyeth, overturning Wyeth’s patent for the extended-release version of the antidepressant drug Effexor-XR.

As explained in our November briefing article, before the Ministry of Foreign Affairs, International Trade and Culture issued Resolution 654/09 on November 2009 that modified Rule 11 of the Rules for the Registration of Domain Names under the country code .ar, the only way to tackle domain name disputes was a court action.

South Africa is a multi-million rand market for complementary and alternative medicines (CAMs), but they are not regulated by the Medicines and Related Substances Act 101 of 1965. However, proposed amendments to the General Regulations in terms of the Act may alter this situation radically, with CAMs becoming subject to regulation by the Medicine Control Council (MCC) of South Africa. The MCC has in turn published guidelines outlining the consequences and requirements that will face the manufacturers of CAMs, which can be summarised as follows.

As director of product management at VeriSign, Sarah Langstone is responsible for educating brands about the new gTLD programme and said she has no time to rest before the application period opens

The Association for Molecular Pathology has asked the US Supreme Court to consider whether isolated DNA sequences are patentable under US law

On Thursday, the Court of Justice’s legal adviser will issue his opinion in a dispute over the ownership of IP rights in football league fixture lists. Managing IP provides a preview

A US government official has defended Icann following the Senate hearing on gTLDs last week where senators said the US government could not unilaterally stop the programme.

Nominet’s senior legal counsel has admitted his growing frustration at a working group that was asked to propose policy changes on seizing .uk domains

Patent attorneys and IP owners who want protection for their stem cell research will soon get new guidance from the European Patent Office about what is, and is not, patentable

Icann will support less wealthy gTLD applicants by asking them to pay only $47,000 in fees, according to Kurt Pritz.